Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19296941 | 0.98 | CYP2B6 (0.63) | CYP2B6CYP2D6KCNH2CHRM2CHRM1 | |
| SCHEMBL2491599 | 0.98 | CYP2B6 (0.63) | CYP2B6CYP2D6KCNH2CHRM2CHRM1 | |
| SCHEMBL9650536 | 0.90 | CYP2B6 (0.46) | CYP2B6CYP2D6KCNH2CHRM2CHRM1 | |
| SCHEMBL2495637 | 0.88 | ESR1 (0.53) | CYP2B6CYP2D6KCNH2CHRM2CHRM1 | |
| SCHEMBL2489520 | 0.86 | CYP2B6 (0.56) | CYP2B6CYP2D6KCNH2CHRM2CHRM1 | |
| SCHEMBL2491636 | 0.86 | CYP2B6 (0.52) | CYP2B6CYP2D6KCNH2CHRM2CHRM1 | |
| SCHEMBL12199488 | 0.86 | CYP2B6 (0.56) | CYP2B6CYP2D6KCNH2CHRM2CHRM1 | |
| SCHEMBL15399522 | 0.84 | CYP2B6 (0.46) | CYP2B6KDM4ESIGMAR1KMT2AMEN1 | |
| SCHEMBL2490819 | 0.82 | CYP2B6 (0.51) | CYP2B6CYP2D6KCNH2LMNASIGMAR1 | |
| SCHEMBL12209773 | 0.82 | CYP2B6 (0.51) | CYP2B6CYP2D6KCNH2LMNASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2380567-B1 | MELANIN PRODUCTION INHIBITOR | POLA CHEM IND INC (JP) | 2019-01-16 | — | — | EP | claimed |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-12-11 | — | — | US | claimed |
| US-8846012-B2 | Melanin production inhibitor | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-30 | — | — | US | claimed |
| EP-2380567-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2011-10-26 | — | — | EP | claimed |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4234042-B1 | MELANOGENESIS INHIBITOR COMPRISING D-PANTOTHENYL ALCOHOL, AND SKIN-WHITENING COSMETIC CONTAINING SAME MELANOGENESIS INHIBITOR | POLA CHEM IND INC (JP) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-4234042-A1 | MELANOGENESIS INHIBITOR COMPRISING D-PANTOTHENYL ALCOHOL, AND SKIN-WHITENING COSMETIC CONTAINING SAME MELANOGENESIS INHIBITOR | Pola Chemical Industries, Inc. (JP) | 2023-08-30 | — | — | EP | disclosed |
| EP-3708148-B1 | MELANOGENESIS INHIBITOR COMPRISING D-PANTOTHENYL ALCOHOL, AND SKIN-WHITENING COSMETIC CONTAINING SAME MELANOGENESIS INHIBITOR | POLA CHEM IND INC (JP) | 2023-07-19 | — | — | EP | disclosed |
| EP-3708148-B1 | MELANOGENESIS INHIBITOR COMPRISING D-PANTOTHENYL ALCOHOL, AND SKIN-WHITENING COSMETIC CONTAINING SAME MELANOGENESIS INHIBITOR | POLA CHEM IND INC (JP) | 2023-07-19 | — | — | EP | disclosed |
| CN-112402279-A | Whitening cosmetic and use of composition containing D-panthenol in preparation of whitening cosmetic | 宝丽化成工业有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-7235577-B1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1562590-A4 | COMPOUNDS, METHODS AND DEVICES FOR INHIBITING NEOPROLIFERATIVE CHANGES IN BLOOD VESSEL WALLS | UNIV CALIFORNIA (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-1562590-A2 | COMPOUNDS, METHODS AND DEVICES FOR INHIBITING NEOPROLIFERATIVE CHANGES IN BLOOD VESSEL WALLS | The Regents of the University of California (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1248614-A4 | NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO | UNIV CALIFORNIA (US) | 2005-05-04 | — | — | EP | disclosed |
| US-6803375-B1 | IMMUNOMODULATION IN A MAMMALIAN PATIENT WITHOUT CAUSING SUBSTANTIAL INHIBITION OF CYTOCHROME P-450 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-10-12 | — | — | US | disclosed |
| WO-2004039330-A2 | COMPOUNDS, METHODS AND DEVICES FOR INHIBITING NEOPROLIFERATIVE CHANGES IN BLOOD VESSEL WALLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-05-13 | — | — | WO | disclosed |
| EP-1248614-A2 | NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO | The Regents of The University of California (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001049663-A2 | NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, TH | CYP2B6 105/4885CYP2D6 141/4885KCNH2 2662/4885 |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, MC1R | CYP2B6 110/4885CYP2D6 137/4885KCNH2 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.